These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 19270449)

  • 1. Mesna for the treatment of hyperhomocysteinemia in hemodialysis patients.
    Cutler MJ; Urquhart BL; Freeman DJ; Spence JD; House AA
    Blood Purif; 2009; 27(3):306-10. PubMed ID: 19270449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of mesna on plasma total homocysteine concentration in hemodialysis patients.
    Urquhart BL; Freeman DJ; Spence JD; House AA
    Am J Kidney Dis; 2007 Jan; 49(1):109-17. PubMed ID: 17185151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The treatment of hyperhomocysteinemia in patients on dialysis: folic acid or the high-flow polysulphonic membrane?].
    Lovcić V; Kes P; Zeljko R; Kusec V
    Acta Med Croatica; 2006 Jun; 60(3):201-8. PubMed ID: 16933832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD.
    Gonin JM; Nguyen H; Gonin R; Sarna A; Michels A; Masri-Imad F; Bommareddy G; Chassaing C; Wainer I; Loya A; Cary D; Barker LF; Assefi A; Greenspan R; Mahoney D; Wilcox CS
    J Nephrol; 2003; 16(4):522-34. PubMed ID: 14696754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dimercaptosuccinic acid for the treatment of hyperhomocysteinemia in hemodialysis patients: a placebo-controlled, double-blind, randomized trial.
    House AA; Eliasziw M; Urquhart BL; Freeman DJ; Spence JD
    Am J Kidney Dis; 2004 Oct; 44(4):689-94. PubMed ID: 15384020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous administration of vitamin B12 in the treatment of hyperhomocysteinemia associated with end-stage renal disease.
    Vrentzos GE; Papadakis JA; Vardakis KE; Maliaraki N; Stilianou K; Arvanitis A; Sratigis S; Alivanis P; Margioris AN; Ganotakis ES
    J Nephrol; 2003; 16(4):535-9. PubMed ID: 14696755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesna for treatment of hyperhomocysteinemia in hemodialysis patients: a placebo-controlled, double-blind, randomized trial.
    Urquhart BL; Freeman DJ; Cutler MJ; Mainra R; Spence JD; House AA
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1041-7. PubMed ID: 18337551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events.
    Vianna AC; Mocelin AJ; Matsuo T; Morais-Filho D; Largura A; Delfino VA; Soares AE; Matni AM
    Hemodial Int; 2007 Apr; 11(2):210-6. PubMed ID: 17403173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omega-3 fatty acid supplementation and total homocysteine levels in end-stage renal disease patients.
    Beavers KM; Beavers DP; Bowden RG; Wilson RL; Gentile M
    Nephrology (Carlton); 2008 Jun; 13(4):284-8. PubMed ID: 18331436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Characteristics of hyperhomocysteinemia in dialysis patients].
    Lovcić V; Kes P; Reiner Z
    Acta Med Croatica; 2006; 60(1):21-6. PubMed ID: 16802568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma reduced homocysteine and other aminothiol concentrations in patients with CKD.
    Sjöberg B; Anderstam B; Suliman M; Alvestrand A
    Am J Kidney Dis; 2006 Jan; 47(1):60-71. PubMed ID: 16377386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hyperhomocysteinemia and advancement of atherosclerosis in patients with chronic renal failure on maintenance hemodialysis].
    Sydor A; Drozdz M; Kraśniak A; Miłkowski A; Chmiel G; Małczak J; Zabawa-Hołyś S; Moskal K; Podwysocki A; Szmigielski M; Czarnecka D; Gozdecka H; Kowalczyk-Michałek M; Szczeklik A; Wiecek A; Sułowicz W
    Przegl Lek; 2002; 59(12):962-7. PubMed ID: 12731367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homocysteine and vascular access thrombosis in end-stage renal disease patients: a retrospective study.
    Bowden RG; Wyatt FB; Wilson R
    J Nephrol; 2002; 15(6):666-70. PubMed ID: 12495281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of folate and vitamin B12 in lowering homocysteine concentrations in hemodialysis patients.
    Azadibakhsh N; Hosseini RS; Atabak S; Nateghiyan N; Golestan B; Rad AH
    Saudi J Kidney Dis Transpl; 2009 Sep; 20(5):779-88. PubMed ID: 19736473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated homocysteine levels in patients with end-stage renal disease.
    Nair AP; Nemirovsky D; Kim M; Geer EB; Farkouh ME; Winston J; Halperin JL; Robbins MJ
    Mt Sinai J Med; 2005 Nov; 72(6):365-73. PubMed ID: 16358160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parenteral vitamin B12 therapy of hyperhomocysteinemia in end-stage renal disease.
    Hoffer LJ; Elian KM
    Clin Invest Med; 2004 Feb; 27(1):10-3. PubMed ID: 15061579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between hyperhomocysteinemia and atherosclerosis in chronic hemodialysis patients.
    Taruangsri P; Ong-Ajyooth L; Ong-Ajyooth S; Chaiyasoot W; Leowattana W; Sritippayawan S; Vareesangthip K; Chanchairujira T; Vasuvattakul S; Shayakul C; Vanichakarn S
    J Med Assoc Thai; 2005 Oct; 88(10):1373-81. PubMed ID: 16519382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effects of hydroxocobalamin and cyanocobalamin on plasma homocysteine concentrations in end-stage renal disease.
    Hoffer LJ; Djahangirian O; Bourgouin PE; Eid J; Saboohi F
    Metabolism; 2005 Oct; 54(10):1362-7. PubMed ID: 16154437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperhomocysteinemia and end-stage renal disease: determinants and association with cardiovascular disease in Tunisian patients.
    Fellah H; Feki M; Hsairi M; Sanhaji H; Kaabachi N; Ben Abdallah T; Massy ZA; Ben Maiz H; Lacour B; Mebazaa A
    Clin Chem Lab Med; 2003 May; 41(5):675-80. PubMed ID: 12812266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folic acid therapy reduces plasma homocysteine levels and improves plasma antioxidant capacity in hemodialysis patients.
    Alvares Delfino VD; de Andrade Vianna AC; Mocelin AJ; Barbosa DS; Mise RA; Matsuo T
    Nutrition; 2007 Mar; 23(3):242-7. PubMed ID: 17321110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.